- Home
- LXEO vs AKBA Comparison
LXEO vs AKBA Comparison
Compare LXEO & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LXEO | AKBA |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 663.5M | 729.1M |
| IPO Year | 2023 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LXEO | AKBA |
|---|---|---|
| Price | $9.38 | $1.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $18.22 | $6.25 |
| AVG Volume (30 Days) | 1.2M | ★ 5.0M |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $225,071,000.00 |
| Revenue This Year | N/A | $52.38 |
| Revenue Next Year | N/A | $22.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 32.49 |
| 52 Week Low | $1.45 | $1.45 |
| 52 Week High | $10.38 | $4.08 |
Technical Indicators
Market Signals| Indicator | LXEO | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 53.99 | 34.61 |
| Support Level | $9.27 | $1.45 |
| Resistance Level | $10.04 | $1.61 |
| Average True Range (ATR) | 0.63 | 0.10 |
| MACD | -0.08 | 0.04 |
| Stochastic Oscillator | 59.94 | 24.36 |
Price Performance
Historical ComparisonAbout LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.